Payment overview · 2025
General Payments
$892.31
51 reported records · 13 companies
Healthcare provider profile · identity verified
Beau Brouillette, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MARKSVILLE, LA · NPI 1457353682
Verified facts
What the public records show
CMS Open Payments records show Beau Brouillette, M.D. received $892.31 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 305 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $294.58 | 33.0% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $162.12 | 18.2% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.35 | 8.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.93 | 8.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $58.48 | 6.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $57.83 | 6.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.78 | 4.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.17 | 3.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.84 | 3.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.85 | 2.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.18 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.47 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.73 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $892.31 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $162.12 | 21 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $132.50 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.26 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $96.23 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $70.93 | 3 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $58.48 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $57.83 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $38.73 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.17 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.84 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.64 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.64 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 305 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 233 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 191 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
94 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
305 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
191 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
233 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1511 | 357 |
| Amlodipine Besylate | Amlodipine Besylate | 956 | 223 |
| Pantoprazole Sodium | Pantoprazole Sodium | 881 | 210 |
| Lisinopril | Lisinopril | 796 | 191 |
| Levothyroxine Sodium | Levothyroxine Sodium | 619 | 111 |
| Metformin Hcl | Metformin Hcl | 603 | 148 |
| Gabapentin | Gabapentin | 532 | 124 |
| Alprazolam | Alprazolam | 518 | 73 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 475 | 162 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 472 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 441 | 180 |
| Furosemide | Furosemide | 440 | 111 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 436 | 122 |
| Escitalopram Oxalate | Escitalopram Oxalate | 424 | 98 |
| Omeprazole | Omeprazole | 383 | 77 |
| Meloxicam | Meloxicam | 370 | 83 |
| Tizanidine Hcl | Tizanidine Hcl | 362 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 343 | 87 |
| Potassium Chloride | Potassium Chloride | 341 | 82 |
| Losartan Potassium | Losartan Potassium | 331 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 326 | 85 |
| Montelukast Sodium | Montelukast Sodium | 320 | 85 |
| Farxiga | Dapagliflozin Propanediol | 305 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 75 |
| Trazodone Hcl | Trazodone Hcl | 277 | 58 |
| Carvedilol | Carvedilol | 269 | 70 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 257 | 66 |
| Mounjaro | Tirzepatide | 244 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 50 |
| Ozempic | Semaglutide | 233 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 226 | 59 |
| Diclofenac Sodium | Diclofenac Sodium | 203 | 72 |
| Buspirone Hcl | Buspirone Hcl | 195 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 191 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 190 | 46 |
| Tramadol Hcl | Tramadol Hcl | 179 | 43 |
| Jardiance | Empagliflozin | 177 | 49 |
| Allopurinol | Allopurinol | 172 | 33 |
| Amoxicillin | Amoxicillin | 159 | 129 |
| Ibuprofen | Ibuprofen | 159 | 54 |
| Ropinirole Hcl | Ropinirole Hcl | 153 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 26 |
| Valsartan | Valsartan | 141 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 140 | 24 |
| Simvastatin | Simvastatin | 140 | 33 |
| Celecoxib | Celecoxib | 138 | 33 |
| Clonazepam | Clonazepam | 129 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 128 | 69 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 127 | 25 |
| Azithromycin | Azithromycin | 126 | 108 |
| Meclizine Hcl | Meclizine Hcl | 121 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 16 |
| Famotidine | Famotidine | 115 | 29 |
| Sertraline Hcl | Sertraline Hcl | 113 | 34 |
| Glimepiride | Glimepiride | 112 | 27 |
| Tresiba Flextouch U-200 | Insulin Degludec | 110 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 35 |
| Ezetimibe | Ezetimibe | 106 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 102 | 18 |
| Eliquis | Apixaban | 102 | 22 |
| Methylprednisolone | Methylprednisolone | 101 | 86 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 24 |
| Linzess | Linaclotide | 94 | 23 |
| Bupropion Xl | Bupropion Hcl | 93 | 17 |
| Trulicity | Dulaglutide | 89 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 13 |
| Aripiprazole | Aripiprazole | 85 | 12 |
| Alendronate Sodium | Alendronate Sodium | 83 | 23 |
| Trintellix | Vortioxetine Hydrobromide | 82 | 14 |
| Donepezil Hcl | Donepezil Hcl | 77 | 19 |
| Lorazepam | Lorazepam | 76 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 18 |
| Xarelto | Rivaroxaban | 76 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 74 | 15 |
| Mupirocin | Mupirocin | 74 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 70 | 12 |
| Prednisone | Prednisone | 70 | 51 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 66 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 20 |
| Clonidine Hcl | Clonidine Hcl | 64 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 34 |
| Nifedipine Er | Nifedipine | 61 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 51 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 49 |
| Pregabalin | Pregabalin | 58 | 20 |
| Rybelsus | Semaglutide | 58 | suppressed |
| Myrbetriq | Mirabegron | 57 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 46 |
| Estradiol | Estradiol | 54 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 50 | suppressed |
| Nystatin | Nystatin | 50 | 25 |
| Dapagliflozin | Dapagliflozin Propanediol | 47 | 21 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 46 | 15 |
| Hydrocortisone | Hydrocortisone | 46 | 18 |
| Doxepin Hcl | Doxepin Hcl | 45 | 12 |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Naproxen | Naproxen | 45 | 11 |
| Mirtazapine | Mirtazapine | 44 | 11 |
| Risperidone | Risperidone | 44 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 14 |
| Diazepam | Diazepam | 38 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 38 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 37 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 19 |
| Colchicine | Colchicine | 34 | 12 |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 16 |
| Baclofen | Baclofen | 31 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 13 |
| Sucralfate | Sucralfate | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Ibu | Ibuprofen | 25 | 13 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | 12 |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Victoza 3-Pak | Liraglutide | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 13 |
| Novolog | Insulin Aspart | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Metolazone | Metolazone | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Viberzi | Eluxadoline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $892.31 · 51 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, Cologuard Collection Kit, FARXIGA, General - Vascular Intervention, IBSRELA, INGREZZA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error